Option chain shows key data for Bebuzee's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bebuzee.

Bebuzee (OTC:BBUZ) Stock, Option Chain

Bebuzee Inc is a social platform and streaming service focused on the development and deployment of America's first SuperApp. The SuperApp will allow members to watch a wide variety of content such as movies, series, documentaries, and talk shows on any internet-connected device. The company's technology scans the world's news, features, and information flow to give its dedicated readers the pace of the Internet in one place.

Bebuzee Inc

Morgan Stanley analyst Richard Hill downgrades Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) from Overweight to Equal-Weight and lowers the price target from $30 to $19.

News

Downgrades

Price Target

Analyst Ratings

SAFE

Morgan Stanley Downgrades Safehold to Equal-Weight, Lowers Price Target to $19

New AI-powered solutions address generative AI, legacy modernization and data analytics to solve industry-specific challenges
NEWTOWN, Pa., Jan. 15, 2025 /PRNewswire/ --&nbsp;<a href="https://www.epam.com/?utm_source=pr-newswire&amp;utm_medium=press-release&amp;utm_campaign=partner-google-cloud&amp;utm_term=sca">EPAM Systems, Inc.</a>&nbsp;(NYSE:<a href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>), a leading digital transformation services and product engineering company,&nbsp;today announced it has <a href="https://www.epam.com/services/partners/google-cloud/?utm_source=pr-newswire&amp;utm_medium=press-release&amp;utm_campaign=partner-google-cloud&amp;utm_term=sca">expanded its strategic partnership with Google Cloud</a> to deliver innovative industry solutions for clients across the media and entertainment, energy and retail verticals. The enhanced collaboration will leverage Google Cloud's Vertex AI platform to drive measurable business outcomes for clients through generative AI, legacy modernization and data analytics capabilities.

EPAM

EPAM Expands Collaboration With Google Cloud To Deliver Scalable AI Solutions For Industry Transformation

FactSet Highlights Launch Of AI-Powered Pitch Creator

Financial analysts are bracing for a potentially volatile week as markets grapple with inflationary concerns and the looming <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42908193/exclusive-answering-key-questions-about-bitcoins-future-before-inauguration">inauguration of Donald Trump.</a>.
A preview of the December Consumer Price Index (CPI) suggests persistently elevated inflation, despite a recent dip in the <a href="https://www.benzinga.com/25/01/42973016/producer-prices-rise-less-than-expected-offer-opportunity-for-market-rebound">Producer Price Index</a> (PPI), raising fears among investors and impacting bond yields and equity markets.
The specter of inflation continues to haunt U.S. markets as the anticipated December CPI data approaches. 
While the U.S. job market remains robust, with non-farm payrolls surpassing expectations, analysts suggest that this could ironically contribute to market unease. 
Predictions for the CPI show expectations of a year-over-year (YoY) increase of 2.8%, slightly up from November&#8217;s 2.7%, and a month-over-month (MoM) rise of 0.3%, matching the previous month&#8217;s rate. 
Core CPI is predicted to remain steady at 3.3% YoY, with a slight decrease to 0.2% MoM. 
These figures, even if in line with expectations, indicate that inflation is still not significantly slowing, with the Fed's 2% target still a distance away.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42998035/bitcoin-adoption-still-early-blackrock-says">Bitcoin Adoption Still Early, BlackRock Says</a>
QCP Capital <a href="https://www.qcpgroup.com/insights/asia-color-34/">noted</a> that Trump&#8217;s imminent inauguration on Jan. 20 has already injected volatility into global markets.
His publicized plans for tariffs, particularly on imports from China, have further fueled inflationary concerns, though there is an expectation for a gradual implementation of these policies. 
As a consequence, bond yields have seen a resurgence, with markets now pricing in only two rate cuts for 2025 and 2026. 
This contrasts with the Federal Reserve&#8217;s prior projection of four cuts, and the 10-year and 30-year US Treasury yields are nearing the 5% mark.
These macro-economic pressures have prompted a decline in risk assets. 
The S&amp;P 500 flirted with breaking below $5,800 and Bitcoin briefly dropped below $90,000 on Monday, demonstrating market fragility.
Bitcoin is trading around $97,000 at the time of writing, up 1%.
However, QCP Capital points out that Trump's actual policies often deviate from his rhetoric, and inflation may not prove as severe as anticipated, and the new administration may also be crypto-friendly.
Benjamin Cowen, CEO of Into The Cryptoverse, also weighed in on how the upcoming CPI release could influence markets, <a href="https://x.com/intocryptoverse/status/1879394089952502102">stating </a>that while strong employment numbers are currently perceived as bad news, due to questions they raise about the Fed's rate-cutting policy, good news on the inflation front could slow down the rise of longer-term Treasury yields.
&#8220;If inflation is not as bad as expected, then it would likely help slow the long end down from this rise,&#8221; he said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42987165/bitcoin-is-an-excellent-buying-opportunity-at-if-it-breaks-below-90000-says-standard-chartered">Bitcoin Is An &#8216;Excellent&#8217; Buying Opportunity At If It Breaks Below $90,000 Says Standard Chartered</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Up 1%, Braces For Volatility Ahead Of Inflation Data Release

Biotech

General

WINT

Windtree Announces Japanese Patent Titled "Inhibitors of atypical protein kinase C (aPKCi) and their use in treating hedgehog pathway-dependent cancers." Expiring In 2040

<ul>
<li>H1 Revenue Surge: Projecting $9M in total revenue, up 218% from the prior year, with strong momentum expected throughout 2025.</li>
<li>Nation's Largest Warehouse Club: Expands BranchOut's product count and regional footprint across four major markets, driving $4M in H1 sales.</li>
<li>Peru Facility Fully Operational: BranchOut celebrates the shipment of its first three containers, with three GentleDry&#x2122; production lines now running and exceeding $40M in annual capacity.</li>
<li>Positive Cash Flow: On track to inflect to positive cash flow beginning in Q1 2025, driven by increased demand and cost efficiencies.</li>
</ul>
BEND, Ore., Jan. 15, 2025 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>), a pioneer in the patented GentleDry&#x2122; dehydration technology, today announced record-breaking growth projections of $9 million in H1 2025 revenue, marking a 218% year-over-year increase. The growth is fueled by $4M from the nation's largest warehouse club, after 2024 sales velocity hit nearly double the retailer's expectations. The strong performance has led to an expansion of BranchOut's product count and regional presence, breaking tradition with a retailer that typically prioritizes single-product offerings.

Guidance

BranchOut Projects $9M H1 2025 Revenue With 218% Growth, Expands In Four Markets Driving $4M Sales, Peru Facility Exceeds $40M Capacity

Artificial intelligence quite evidently seems to have been a growth driver for computer memory and data storage specialist Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>). Throughout the first half of last year, MU stock shot skyward, at one point exceeding $150 per share. However, starting from the back half of 2024, momentum noticeably faded, leading to questions about forward viability.
On paper, many expect Micron to easily hitch a ride on the waves of the broader innovation ecosystem. For example, a study released last year by Cognizant Impact estimated that generative AI will<a href="https://www.benzinga.com/news/24/01/36588991/study-forecasts-staggering-1-trillion-boost-to-us-economy-with-generative-ai-but-warns-of-job-disrup"> spark a $1 trillion impact</a> for the U.S. economy within the next ten years. Such rapid integration – and disruption – calls for infrastructural upgrades, a dynamic that organically benefits Micron.
At the same time, this bullish assessment hasn't always lifted MU stock. In particular, Micron seems to have failed to deliver the goods for its fiscal first quarter, posting revenue of $8.71 billion and thus<a href="https://www.benzinga.com/news/earnings/24/12/42564387/micron-q1-earnings-revenue-miss-eps-beat-soft-guidance-sinks-shares-as-consumer-markets-turn-weaker-in-near-term"> slightly missing the consensus estimate</a> of $8.72 billion. It did, however, post adjusted earnings per share of $1.79, exceeding the expected view of $1.76.
Nevertheless, many investors quickly rushed for the exits, leading to volatility for MU stock. Management admitted to consumer-oriented markets being weaker in the near term, which raised questions about excessive valuations amid an apparently slowing market.
Despite the challenges, it seems that bulls may have begun to view the latest volatility as a deep-value proposition. Since the end of December, MU stock has gained almost 16%, buoyed by the promises of a strong second-half setup. Specifically,<a href="https://www.benzinga.com/trading-ideas/25/01/42924357/nvidia-marvell-synopsys-demonstrate-ai-leadership-and-strong-chip-design-momentum-analyst"> AI-driven demand</a> for high bandwidth memory (HBM) and enterprise solid-state drives (eSSDs) may boost sales, along with a cyclical recovery in non-AI segments such as smartphones and PCs.
The Direxion ETFs: Investors wanting to jump into the fray but without the complexities of advanced trading strategies may consider two Micron-focused exchange-traded funds. First, the Direxion Daily MU Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MUU#NASDAQ">MUU</a>) is a leveraged fund that seeks daily investment results of 200% of the performance of MU stock.
Second, those who are bearish on Micron's prospects may consider the Direxion Daily MU Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MUD#NASDAQ">MUD</a>), which seeks 100% of the inverse performance of MU. Both funds can be traded just like any other security, offering convenience for speculators. However, it must be noted that exposure to MUU and MUD should not last longer than one day due to the daily compounding effect.
The MUU ETF: Making its debut in October last year, Direxion's 2X MU bull fund has broadly suffered due to timing, losing almost 26%. Nevertheless, recent sessions have shown some promise for bullish speculators.
<ul>
<li>Earlier this month, MUU fell straight through the critical $20 support level. Quickly, the bulls mounted a recovery rally, bringing the price back above this psychologically significant milestone.</li>
<li>Moving forward, it appears important that the optimists establish control, with the first major priority being a jump to technical resistance at $22.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcN42PPYls5uZpluUMJnqnKRFv52jlW4wWRd_9IrzZNP2he11aJVIAQiDxixpgAZfELIQND2t7heDW9bcN5t-rRDA8FoEov_OUDSXWiR27Wb1V9GhZKtXU1huYfP3mXYp3PWTq7?key=FvMeZgFOuSoPryt4lBpU4JB_" alt="" /></figure>
The MUD ETF: Also making its debut last October, Direxion's MU bear fund has witnessed a smoother journey, gaining just over 2%. Still, some recent volatility presents questions for Micron pessimists.
<ul>
<li>MUD has consistently traded above the $22 support line, which is imperative to avoid a costly trend reversal.</li>
<li>However, for the bears to build momentum, the inverse fund would need to secure the $25 level. From there, a return to $28 to stage a push to $30 would be the next logical target.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfrv1huZpe7VzcpdKtIulo9a9ApFZHUxrUPuAprC_cYX_t0j8XOwl2KDBNboIh3kGi_X9B0NTlT-42tQbTo7SHRlR8hQdfi2vAICCJUl1dsHkYj4ecAv1BlkqwXBQpynwEuAuNq2A?key=FvMeZgFOuSoPryt4lBpU4JB_" alt="" /></figure>
Featured photo by <a href="https://pixabay.com/users/blickpixel-52945/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=453758">Michael Schwarzenberger</a> on <a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=453758">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

Direxion's Micron Bull And Bear ETFs Allow Investors To Trade The Tech Tug-of-War

Citigroup Sees FY25 Revenue $83.5B-$84.5B Vs $83.24B Est

Morgan Stanley analyst Ronald Kamdem upgrades CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) from Equal-Weight to Overweight and raises the price target from $115 to $160.

Upgrades

CBRE

Morgan Stanley Upgrades CBRE Group to Overweight, Raises Price Target to $160

Mercurity Fintech Holding Inc. (the "Company," "we," "us," "our company," or "MFH") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>), a digital fintech group, is pleased to announce the pricing of another private investment in public equity (the "PIPE") financing. On January 9, 2025, the Company entered into a securities purchase agreement and priced the PIPE offering, pursuant to which it sold an aggregate of 1,370,000 ordinary shares to one institutional investor at a price of US$5.87 per share. The financing is priced at-the-market under Nasdaq rules, representing 100% of the closing price of the Company's shares on January 8, 2025. The offering resulted in total gross proceeds of approximately US$8,041,900 ("Gross Proceeds") before deducting fees and offering expenses payable by the Company.
Subject to customary closing conditions, the PIPE is expected to close on or before January 17, 2025. The securities described above were sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements.
This PIPE investment comes just weeks after the Company's successful closing of a previous US$10 million PIPE offering with the same institutional investor on December 19, 2024, at US$6.81 per share.

Offerings

Mercurity Fintech Announces The Pricing Of Another Private Investment In Public Equity Financing. On January 9, 2025, The Company Entered Into A Securities Purchase Agreement And Priced The PIPE Offering, Pursuant To Which It Sold An Aggregate Of 1.37M Ordinary Shares To One Institutional Investor At A Price Of $5.87 Per Share

LUXH

LuxUrban Sees 2025 Revenue $62M-$67M

Genius Sports Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) ("Genius Sports," the "Company," "we" or "our") announced today the pricing of an underwritten public offering of 17,647,059 ordinary shares, par value $0.01 (the "Ordinary Shares"), by the Company at a price to the public of $8.50 per Ordinary Share. The offering is expected to close on January 16, 2025, subject to the satisfaction of customary closing conditions.
The Company estimates the net proceeds from the offering will be approximately $144 million, after deducting the underwriting commissions and estimated offering expenses. The Company currently expects to use the net proceeds from this offering for general corporate purposes, which may include the acquisition or investment in complementary businesses, technologies or other assets, although the Company currently has no agreements or understandings with respect to any such acquisitions or investments.
The offering included participation from Caledonia and Wellington Management, among other top existing shareholders as well as new investors.

GENI

Genius Sports Announces Pricing Of $144M Public Offering Of 17,647,059 Ordinary Shares At A Price To The Public Of $8.50 Per Ordinary Share

WIIM

Citigroup shares are trading higher after the company reported better-than-expected Q4 financial results and announced a $20 billion buyback

Johnson & Johnson Initiates Submission Of New Drug Application With FDA For TAR-200 In BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer

<ul>
<li>ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile</li>
</ul>
UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February issue of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.auajournals.org%2Fdoi%2F10.1097%2FJU.0000000000004296&amp;esheet=54180006&amp;newsitemid=20250115929797&amp;lan=en-US&amp;anchor=The+Journal+of+Urology&amp;index=1&amp;md5=45dddb06f66d1cd53513343d492a0608">The Journal of Urology</a>.
In the ENVISION trial, UGN-102 treatment demonstrated an impressive 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) by Kaplan-Meier estimate (n=108) in patients who achieved a CR at three months after the first instillation of UGN-102 (mitomycin) for intravesical solution. The Kaplan-Meier estimates for DOR at 15 months (n=43) and 18 months (n=9) following the 3-month CR were both 80.9% (95% CI, 73.9%, 86.2%). The ENVISION trial also met its primary endpoint, showing a 79.6% (95% CI, 73.9%, 84.5%) CR rate at three months in patients treated with UGN-102.

URGN

UroGen Pharma Reports ENVISION Trial Results Published In The February Issue Of The Journal Of Urology Highlight UGN-102 Achievement Of 82.3% Duration Of Response at 12 Months Paving The Way For The Potential First FDA-Approved Treatment For LG-IR-NMIBC In June 2025

CERT

Certara Sees Q4 Revenues Of $99.7M, compared to $88M YoY, Sees Q4 Bookings of $144.5M

Northland Capital Markets analyst Michael Latimore maintains Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) with a Outperform and raises the price target from $16 to $23.

SERV

Northland Capital Markets Maintains Outperform on Serve Robotics, Raises Price Target to $23

Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.22 by 9.84 percent. The company reported quarterly sales of $19.58 billion which beat the analyst consensus estimate of $19.48 billion by 0.52 percent. This is a 12.28 percent increase over sales of $17.44 billion the same period last year.

Earnings

Earnings Beats

Citigroup Q4 2024 Adj EPS $1.34 Beats $1.22 Estimate, Sales $19.58B Beat $19.48B Estimate

Ratings for Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.75, with a high estimate of $82.00 and a low estimate of $55.00. Witnessing a positive shift, the current average has risen by 21.3% from the previous average price target of $57.50.
<img src="https://www.benzinga.com/files/images/story/2025/1736946099_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Affirm Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Bryan Keane</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Affirm Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Affirm Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Affirm Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Affirm Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AFRM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Affirm Holdings analyst ratings.</a>
<h2>About Affirm Holdings</h2>
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
<h3>Affirm Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Affirm Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 40.67% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Affirm Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -14.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Affirm Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -3.6%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Affirm Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.51, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFRM

Deep Dive Into Affirm Holdings Stock: Analyst Perspectives (12 Ratings)

Throughout the last three months, 5 analysts have evaluated Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Vericel, revealing an average target of $62.6, a high estimate of $67.00, and a low estimate of $60.00. This current average has increased by 5.39% from the previous average price target of $59.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1736946087_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Vericel by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vericel. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vericel compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vericel's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vericel analyst ratings.</a>
<h2>About Vericel</h2>
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
<h3>Vericel's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Vericel displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 27.04%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.36%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Vericel's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Vericel adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VCEL

Beyond The Numbers: 5 Analysts Discuss Vericel Stock

Press Releases

From Beta to Breakthrough: Bebuzee Prepares to Launch Its Game-Changing Super App to Global Users

Contracts

IBN Coverage Initiated for Bebuzee Inc.

Bebuzee's Revolutionary Super App Will Disrupt US and European Markets

Bebuzee, Inc. Unveils New and Exciting Live Streaming Features in Its Revolutionary Super App

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Joe Onyero, CEO of Bebuzee Inc.

Bebuzee, Inc. Unveils the First Super App for America and Europe: 'Bebuzee,' a Revolutionary Digital Ecosystem

Bebuzee, Inc. Announces Exciting Launch of Groundbreaking SuperApp on August 30th, 2024

Bebuzee Introduces TV Channels on Its Super App: Revolutionizing Entertainment on a Single Platform

Bebuzee Revolutionizes Content Creation With Revenue-Earning Features for Creators Worldwide

BBUZ

ENGA

Bebuzee

Comments

Bebuzee

Bebuzee (BBUZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga